
MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition
Keywords: Cancer; Therapy; p53; V-ATPase; Nutlin-3a; V-ATPase; vacuolar-type ATPase; OXPHOS; oxidative phosphorylation; TIGAR; TP53-induced glycolysis and apoptosis regulator; U87; U87MG; IGFBP3; insulin-like growth factor-binding protein 3;